What is Cue Biopharma (CUE) stock price today?

Cue Biopharma (CUE) currently trades at $14.74 per share. The stock has a market capitalization of $57.60M and a P/E ratio of —x.

Is CUE stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Cue Biopharma has a Smart Value Score of 34/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 2/9 and Altman Z-Score is -15.59.

What is Cue Biopharma's revenue and earnings?

Cue Biopharma has trailing twelve-month (TTM) revenue of $27.47M with profit margins of -96.90%. Earnings per share (EPS) is $-8.40.

Is Cue Biopharma financially healthy?

Cue Biopharma's Piotroski F-Score is 2/9 (weak financial health). The Altman Z-Score of -15.59 places it in the distress.

CUE

Cue Biopharma

NASDAQ: CUE · HEALTHCARE · BIOTECHNOLOGY

$14.74

+13.38% today

Updated 2026-04-30

Market cap

$57.60M

P/E ratio

—

P/S ratio

2.10x

EPS (TTM)

$-8.40

Dividend yield

—

52W range

$5 – $31

Volume

11.4M

Market cap

$57.60M

P/E ratio

—

P/S ratio

2.10x

EPS (TTM)

$-8.40

Dividend yield

—

52W range

$5 – $31

Volume

11.4M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

8.0

Growth

5.0

Quality

C+

3.0

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

-15.6

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →201 stocks currently score above 75

Price targets

Analyst target

$120.00

+714.11%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Revenue growth 1,292.00% QoQ

+ Debt/equity 0.47x — low leverage

Risks

- Piotroski 2/9 — weak financial health

- Altman Z -15.59 — distress zone

- Thin margins at -96.90%

- Negative free cash flow $-1.08M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$1.25M	$5.49M	$9.29M	$27.47M	$27.47M
Net income	$-53.01M	$-50.73M	$-40.67M	$-26.60M	$1.58M
EPS	—	—	—	—	$-8.40
Free cash flow	$-41.98M	$-39.96M	$-36.40M	$-21.86M	$-1.08M
Profit margin	-4,257.83%	-924.10%	-437.97%	-96.85%	-96.90%

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
CUE	$57.60M	34	8.0	3.0	5.0	5.0	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Cue Biopharma trades at $14.74. Our Smart Value Score of 34/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -15.59, it sits in the distress. TTM revenue stands at $27.47M. with profit margins at -96.90%.

Frequently asked questions

What is Cue Biopharma's stock price?

Cue Biopharma (CUE) trades at $14.74.

Is Cue Biopharma overvalued?

Smart Value Score 34/100 (Grade F, Strong Sell).

What is the price target of Cue Biopharma (CUE)?

The analyst target price is $120.00, representing +714.1% upside from the current price of $14.74.

What is Cue Biopharma's revenue?

TTM revenue is $27.47M.

Piotroski F-Score?

2/9 — weak financial health.

Altman Z-Score?

-15.59 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio2.10x

ROE-121.10%

Beta1.58

50D MA$10.32

200D MA$16.78

Shares out0.00B

Float0.00B

Short ratio—

Avg volume11.4M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

CUE vs LLY →CUE vs JNJ →CUE vs ABBV →Stock screener →